Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease.
Chikamatsu M, Watanabe H, Shintani Y, Murata R, Miyahisa M, Nishinoiri A, Imafuku T, Takano M, Arimura N, Yamada K, Kamimura M, Mukai B, Satoh T, Maeda H, Maruyama T.
Chikamatsu M, et al. Among authors: maeda h.
J Control Release. 2023 Mar;355:42-53. doi: 10.1016/j.jconrel.2023.01.039. Epub 2023 Feb 1.
J Control Release. 2023.
PMID: 36690035